An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 87-100

  Karhemo, Piia Riitta ^a,f   Ravela, Suvi ^a   Laakso, Marko ^a   Ritamo, Ilja ^b   Tatti, Olga ^a,c,f   Mäkinen, Selina ^a,f   Goodison, Steve ^d   Stenman, Ulf Håkan ^a   Hölttä, Erkki ^c   Hautaniemi, Sampsa ^a   Valmu, Leena ^b   Lehti, Kaisa ^a,c   Laakkonen, Pirjo ^a,e,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Finnish Red Cross   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d M D ANDERSON CANCER CENTER ORLANDO   (United States)

^e Foundation for the Finnish Cancer Institute   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Biotinylation; CD109; Cell surface; ITGA6; LC MS MS; Metastasis

Indexed keywords

ALPHA6 INTEGRIN; CD109 PROTEIN; CELL SURFACE PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT; VALIDITY;

BIOTINYLATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEOMICS;

EID: 84870393632     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.009     Document Type: Article

References (67)

1. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.
2. Ossowski L., Aguirre-Ghiso J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010, 23(1):41-56.
3. Auerbach R., Lu W.C., Pardon E., Gumkowski F., Kaminska G., Kaminski M. Specificity of adhesion between murine tumor cells and capillary endothelium: an in vitro correlate of preferential metastasis in vivo. Cancer Res 1987, 47(6):1492-1496.
4. Johnson R.C., Augustin-Voss H.G., Zhu D.Z., Pauli B.U. Endothelial cell membrane vesicles in the study of organ preference of metastasis. Cancer Res 1991, 51(1):394-399.
5. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9(4):274-284.
6. Hopkins A.L., Groom C.R. The druggable genome. Nat Rev Drug Discov 2002, 1(9):727-730.
7. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 2006, 5(12):993-996.
8. Brunet S., et al. Organelle proteomics: looking at less to see more. Trends Cell Biol 2003, 13(12):629-638.
9. Leth-Larsen R., Lund R.R., Ditzel H.J. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 2010, 9(7):1369-1382.
10. Elschenbroich S., Kim Y., Medin J.A., Kislinger T. Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics 2010, 7(1):141-154.
11. Rahbar A.M., Fenselau C. Integration of Jacobson's pellicle method into proteomic strategies for plasma membrane proteins. J Proteome Res 2004, 3(6):1267-1277.
12. Mathias R.A., et al. Tandem application of cationic colloidal silica and Triton X-114 for plasma membrane protein isolation and purification: towards developing an MDCK protein database. Proteomics 2011, 11(7):1238-1253.
13. Elia G. Biotinylation reagents for the study of cell surface proteins. Proteomics 2008, 8(19):4012-4024.
14. Wollscheid B., et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 2009, 27(4):378-386.
15. Ruoslahti E., Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 2000, 18:813-827.
16. Brown D.M., Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004, 5(4):365-374.
17. Dowling P., Walsh N., Clynes M. Membrane and membrane-associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells. Proteomics 2008, 8(19):4054-4065.
18. Brooks S.A., Lomax-Browne H.J., Carter T.M., Kinch C.E., Hall D.M. Molecular interactions in cancer cell metastasis. Acta Histochem 2010, 112(1):3-25.
19. Urquidi V., et al. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 2002, 8(1):61-74.
20. Goodison S., et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 2003, 9(10 Pt 1):3808-3814.
21. Ellison G., Klinowska T., Westwood R.F., Docter E., French T., Fox J.C. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002, 55(5):294-299.
22. Rae J.M., Creighton C.J., Meck J.M., Haddad B.R., Johnson M.D. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007, 104(1):13-19.
23. Ross D.T., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24(3):227-235.
24. Chambers A.F. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res 2009, 69(13):5292-5293.
25. Hollestelle A., Schutte M. Comment re: MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res 2009, 69(19):7893.
26. Schwirzke M., Evtimova V., Burtscher H., Jarsch M., Tarin D., Weidle U.H. Identification of metastasis-associated genes by transcriptional profiling of a pair of metastatic versus non-metastatic human mammary carcinoma cell lines. Anticancer Res 2001, 21(3B):1771-1776.
27. Kreunin P., Urquidi V., Lubman D.M., Goodison S. Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 2004, 4(9):2754-2765.
28. Kreunin P., Yoo C., Urquidi V., Lubman D.M., Goodison S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 2007, 7(2):299-312.
29. Lund R., Leth-Larsen R., Jensen O.N., Ditzel H.J. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res 2009, 8(6):3078-3090.
30. Pasquali C., Fialka I., Huber L.A. Subcellular fractionation, electromigration analysis and mapping of organelles. J Chromatogr B Biomed Sci Appl 1999, 722(1-2):89-102.
31. Tatti O., Arjama M., Ranki A., Weiss S.J., Keski-Oja J., Lehti K. Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS One 2011, 6(12):e28325.
32. Scheurer S.B., et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005, 5(11):2718-2728.
33. Roesli C., Mumprecht V., Neri D., Detmar M. Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J 2008, 22(6):1933-1944.
34. Kinter M., Sherman N.E. Protein sequencing and identification using tandem mass spectrometry 2000, 160-163. John Wiley & Sons, Inc., New York.
35. Laakso M., Hautaniemi S. Integrative platform to translate gene sets to networks. Bioinformatics 2010, 26(14):1802-1803.
36. Wang Y., et al. Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis. Mol Cancer 2011, 10:84.
37. Demetriou M.C., Cress A.E. Integrin clipping: a novel adhesion switch?. J Cell Biochem 2004, 91(1):26-35.
38. Wick N., et al. Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. Physiol Genomics 2007, 28(2):179-192.
39. Wojtukiewicz M.Z., et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990, 93(4):516-521.
40. Neve R.M., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
41. Strassberger V., Trüssel S., Fugmann T., Neri D., Roesli C. A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments. Proteomics 2010, 10(19):3544-3548.
42. Rubin R.W., Quillen M., Corcoran J.J., Ganapathi R., Krishan A. Tubulin as a major cell surface protein in human lymphoid cells of leukemic origin. Cancer Res 1982, 42(4):1384-1389.
43. Quillen M., Castello C., Krishan A., Rubin R.W. Cell surface tubulin in leukemic cells: molecular structure, surface binding, turnover, cell cycle expression, and origin. J Cell Biol 1985, 101(6):2345-2354.
44. Por S.B., Cooley M.A., Breit S.N., Penny R., French P.W. Antibodies to tubulin and actin bind to the surface of a human monocytic cell line, U937. J Histochem Cytochem 1991, 39(7):981-985.
45. Stump D.D., Zhou S.L., Berk P.D. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver. Am J Physiol 1993, 265(5 Pt 1):G894-G902.
46. Bradbury M.W., Berk P.D. Mitochondrial aspartate aminotransferase: direction of a single protein with two distinct functions to two subcellular sites does not require alternative splicing of the mRNA. Biochem J 2000, 345(Pt 3):423-427.
47. Yates J.R., Gilchrist A., Howell K.E., Bergeron J.J. Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Biol 2005, 6(9):702-714.
48. Arap M.A., et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004, 6(3):275-284.
49. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878.
50. Eustace B.K., Jay D.G. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004, 3(9):1098-1100.
51. Melendez K., Wallen E.S., Edwards B.S., Mobarak C.D., Bear D.G., Moseley P.L. Heat shock protein 70 and glycoprotein 96 are differentially expressed on the surface of malignant and nonmalignant breast cells. Cell Stress Chaperones 2006, 11(4):334-342.
52. Fogal V., Zhang L., Krajewski S., Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 2008, 68(17):7210-7218.
53. Qiu H., Wang Y. Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J Proteome Res 2008, 7(5):1904-1915.
54. Klein T., Bischoff R. Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res 2011, 10(1):17-33.
55. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
56. Hartsough M.T., Steeg P.S. Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr 2000, 32(3):301-308.
57. Leth-Larsen R., et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 2009, 8(6):1436-1449.
58. Orlicky D.J. Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP). Prostaglandins Leukot Essent Fatty Acids 1996, 54(4):247-259.
59. Charrin S., et al. The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J Biol Chem 2001, 276(17):14329-14337.
60. Charrin S., et al. Multiple levels of interactions within the tetraspanin web. Biochem Biophys Res Commun 2003, 304(1):107-112.
61. Stipp C.S., Orlicky D., Hemler M.E. FPRP, a major, highly stoichiometric, highly specific CD81- and CD9-associated protein. J Biol Chem 2001, 276(7):4853-4862.
62. Guilmain W., et al. CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth. Br J Cancer 2011, 104(3):496-504.
63. Miles F.L., Pruitt F.L., van Golen K.L., Cooper C.R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis 2008, 25(4):305-324.
64. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
65. Finnson K.W., et al. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J 2006, 20(9):1525-1527.
66. Hagiwara S., et al. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene 2010, 29(15):2181-2191.
67. Ohshima Y., et al. CD109 expression levels in malignant melanoma. J Dermatol Sci 2010, 57(2):140-142.